1887

Abstract

The first Dutch outbreak due to ribotype 027 was observed in mid-2005; by the end of that year, eight hospitals were affected. To study the relationship between hospital-wide antibiotic use and the incidence of 027-linked -associated disease (CDAD) three study groups were made: group A, all eight hospitals with an 027-associated epidemic; group B, five of a total of six hospitals with occasional 027 cases, without an increase in CDAD; and group C, ten randomly selected hospitals with no reported 027 epidemics or isolated 027 cases. Quarterly data on CDAD incidences, hygiene measures and the use of fluoroquinolones, second- and third-generation cephalosporins, extended-spectrum penicillins, penicillins with beta-lactamase inhibitors, carbapenems, lincomycins and macrolides were collected for 2004 and 2005, and divided into pre-epidemic and epidemic periods. Using a multilevel Poisson regression analysis, CDAD incidence was linked to antibiotic use in the previous quarter and to certain hygiene measures. In the pre-epidemic period, the total use of the studied antibiotics was comparable between affected and unaffected hospitals. Higher use of second-generation cephalosporins, macrolides and all of the studied antibiotics were independently associated with a small increase in CDAD incidence [relative risk (95 % confidence interval): 1.14 per increase of 100 defined daily doses per 10 000 bed days (1.06–1.23), 1.10 (1.01–1.19) and 1.02 (1.01–1.03), respectively]. However the effect was too small to predict which hospitals might be more prone to 027-associated outbreaks.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.47711-0
2008-06-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jmm/57/6/709.html?itemId=/content/journal/jmm/10.1099/jmm.0.47711-0&mimeType=html&fmt=ahah

References

  1. Barbut F., Gariazzo B., Bonne L., Lalande V., Burghoffer B., Luiuz R., Petit J. C. 2007; Clinical features of Clostridium difficile -associated infections and molecular characterization of strains: results of a retrospective study, 2000–2004. Infect Control Hosp Epidemiol 28:131–139 [CrossRef]
    [Google Scholar]
  2. Berild D., Smaabrekke L., Halvorsen D. S., Lelek M., Stahlsberg E. M., Ringertz S. H. 2003; Clostridium difficile infections related to antibiotic use and infection control facilities in two university hospitals. J Hosp Infect 54:202–206 [CrossRef]
    [Google Scholar]
  3. Biller P., Shank B., Lind L., Brennan M., Tkatch L., Killgore G., Thompson A., McDonald L. C. 2007; Moxifloxacin therapy as a risk factor for Clostridium difficile -associated disease during an outbreak: attempts to control a new epidemic strain. Infect Control Hosp Epidemiol 28:198–201 [CrossRef]
    [Google Scholar]
  4. Cartmill T. D., Panigrahi H., Worsley M. A., McCann D. C., Nice C. N., Keith E. 1994; Management and control of a large outbreak of diarrhoea due to Clostridium difficile . J Hosp Infect 27:1–15 [CrossRef]
    [Google Scholar]
  5. Chandler R. E., Hedberg K., Cieslak P. R. 2007; Clostridium difficile -associated disease in Oregon: increasing incidence and hospital-level risk factors. Infect Control Hosp Epidemiol 28:116–122 [CrossRef]
    [Google Scholar]
  6. Cherifi S., Delmee M., Van Broeck J., Beyer I., Byl B., Mascart G. 2006; Management of an outbreak of Clostridium difficile -associated disease among geriatric patients. Infect Control Hosp Epidemiol 27:1200–1205 [CrossRef]
    [Google Scholar]
  7. Debast S. B., Vaessen N., Choudry A., van den Berg R., Kuijper E. 2006; Outbreak of Clostridium difficile PCR-ribotype 027 toxinotype III in Harderwijk, the Netherlands. In Abstracts of the 16th European Congress of Clinical Microbiology and Infectious Diseases Nice: 1–4 April 2006 Abstract P1640 http://www.blackwellpublishing.com/eccmid16/abstract.asp?id=50435
    [Google Scholar]
  8. Fawley W. N., Underwood S., Freeman J., Baines S. D., Saxton K., Stephenson K., Owens R. C. Jr, Wilcox M. H. 2007; Efficacy of hospital cleaning agents and germicides against epidemic Clostridium difficile strains. Infect Control Hosp Epidemiol 28:920–925 [CrossRef]
    [Google Scholar]
  9. Gaynes R., Rimland D., Killum E., Lowery H. K., Johnson T. M. II, Killgore G., Tenover F. C. 2004; Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 38:640–645 [CrossRef]
    [Google Scholar]
  10. Goorhuis A., Van der Kooi T., Vaessen N., Dekker F. W., Van den Berg R., Harmanus C., van den Hof S., Notermans D. W., Kuijper E. J. 2007; Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. Clin Infect Dis 45:695–703 [CrossRef]
    [Google Scholar]
  11. Hubert B., Loo V. G., Bourgault A. M., Poirier L., Dascal A., Fortin E., Dionne M., Lorange M. 2007; A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile -associated disease in Quebec. Clin Infect Dis 44:238–244 [CrossRef]
    [Google Scholar]
  12. Johnson S., Gerding D. N. 2004; Clostridium difficile . In Hospital Epidemiology and Infection Control . pp 623–634 Edited by Mayhall G. M. Philadelphia: Lippincott Williams & Wilkins;
  13. Khan R., Cheesbrough J. 2003; Impact of changes in antibiotic policy on Clostridium difficile -associated diarrhoea (CDAD) over a five-year period in a district general hospital. J Hosp Infect 54:104–108 [CrossRef]
    [Google Scholar]
  14. Kuijper E. J., Debast S. B., Van Kregten E., Vaessen N., Notermans D. W., van den Broek P. J. 2005; Clostridium difficile ribotype 027, toxinotype III in The Netherlands. Ned Tijdschr Geneeskd 149:2087–2089
    [Google Scholar]
  15. Kyne L., Merry C., O'Connell B., Harrington P., Keane C., O'Neill D. 1998; Simultaneous outbreaks of two strains of toxigenic Clostridium difficile in a general hospital. J Hosp Infect 38:101–112 [CrossRef]
    [Google Scholar]
  16. Loo V. G., Poirier L., Miller M. A., Oughton M., Libman M. D., Michaud S., Bourgault A. M., Nguyen T., Frenette C. other authors 2005; A predominantly clonal multi-institutional outbreak of Clostridium difficile -associated diarrhea with high morbidity and mortality. N Engl J Med 353:2442–2449 [CrossRef]
    [Google Scholar]
  17. McCusker M. E., Harris A. D., Perencevich E., Roghmann M. C. 2003; Fluoroquinolone use and Clostridium difficile -associated diarrhea. Emerg Infect Dis 9:730–733 [CrossRef]
    [Google Scholar]
  18. McDonald L. C., Killgore G. E., Thompson A., Owens R. C. Jr, Kazakova S. V., Sambol S. P., Johnson S., Gerding D. N. 2005; An epidemic, toxin gene-variant strain of Clostridium difficile . N Engl J Med 353:2433–2441 [CrossRef]
    [Google Scholar]
  19. Modena S., Bearelly D., Swartz K., Friedenberg F. K. 2005; Clostridium difficile among hospitalized patients receiving antibiotics: a case-control study. Infect Control Hosp Epidemiol 26:685–690 [CrossRef]
    [Google Scholar]
  20. Muto C. A., Pokrywka M., Shutt K., Mendelsohn A. B., Nouri K., Posey K., Roberts T., Croyle K., Krystofiak S. other authors 2005; A large outbreak of Clostridium difficile -associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 26:273–280 [CrossRef]
    [Google Scholar]
  21. Muto C. A., Blank M. K., Marsh J. W., Vergis E. N., O'Leary M. M., Shutt K. A., Pasculle A. W., Pokrywka M., Garcia J. G. other authors 2007; Control of an outbreak of infection with the hypervirulent Clostridium difficile B1 strain in a university hospital using a comprehensive “bundle” approach. Clin Infect Dis 45:1266–1273 [CrossRef]
    [Google Scholar]
  22. Notermans D., van Kregten E., Speelman P., Kuijper E. 2005 Maatregelen bij een epidemische verheffing in een ziekenhuis door Clostridium difficile ribotype 027 – toxinotype III Bilthoven, The Netherlands: Centre for Infectious Disease Control/National Institute for Public Health and the Environment; (in Dutch) http://www.rivm.nl/cib/infectieziekten/Clostridium_difficile/Clostridium_difficile_draaiboek.jsp
    [Google Scholar]
  23. O'Connor K. A., Kingston M., O'Donovan M., Cryan B., Twomey C., O'Mahony D. 2004; Antibiotic prescribing policy and Clostridium difficile diarrhoea. QJM 97:423–429 [CrossRef]
    [Google Scholar]
  24. Pepin J., Valiquette L., Alary M. E., Villemure P., Pelletier A., Forget K., Pepin K., Chouinard D. 2004; Clostridium difficile -associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171:466–472 [CrossRef]
    [Google Scholar]
  25. Pepin J., Saheb N., Coulombe M. A., Alary M. E., Corriveau M. P., Authier S., Leblanc M., Rivard G., Bettez M. other authors 2005; Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile -associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41:1254–1260 [CrossRef]
    [Google Scholar]
  26. Salgado C., Fogle P., Harley B., Mauldin P., Bosso J., Cantey J. 2006; Clostridium difficile associated diarrhea outbreak controlled with enhanced infection control measures. In Abstracts of the 16th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America Chicago: 18–21 March 2006 Abstract 190
    [Google Scholar]
  27. Shek F. W., Stacey B. S., Rendell J., Hellier M. D., Hanson P. J. 2000; The rise of Clostridium difficile : the effect of length of stay, patient age and antibiotic use. J Hosp Infect 45:235–237 [CrossRef]
    [Google Scholar]
  28. Siegel J. D., Rhinehart E., Jackson M., Chiarello L. The Healthcare Infection and Control Practices Advisory Committee 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings 2007 Atlanta, GA: Public Health Service, US Department of Health and Human Services, Centers for Disease Control and Prevention; http://www.cdc.gov/ncidod/dhqp/pdf/Isolation2007.pdf
    [Google Scholar]
  29. SWAB 2007 NETHMAP 2007 – Consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in The Netherlands Bilthoven, The Netherlands: RIVM and Stichting Werkgroep Antibioticabeleid; http://www.swab.nl/swab/swabcms.nsf/(WebFiles)/D552D3B6190D0461C12572FF0024F246/$FILE/NETHMAP_2007.pdf
    [Google Scholar]
  30. Valiquette L., Cossette B., Garant M. P., Diab H., Pepin J. 2007; Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile -associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 45 (Suppl. 2):S112–S121 [CrossRef]
    [Google Scholar]
  31. Veenendaal D., Kuijper E. 2007; Successful combat against Clostridium difficile PCR-ribotype 027 at a regional outbreak from 2003–2006 in the Netherlands. In Abstracts of the 17th European Congress of Clinical Microbiology and Infectious Diseases Munich: 31 March–4 April 2007 Abstract 1732_216 http://www.blackwellpublishing.com/eccmid17/abstract.asp?id=56178
    [Google Scholar]
  32. Warny M., Pepin J., Fang A., Killgore G., Thompson A., Brazier J., Frost E., McDonald L. C. 2005; Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366:1079–1084 [CrossRef]
    [Google Scholar]
  33. Weil H.-P., Mattner F., van den Berg R., Gastmeier P., Kuijper E., Fischer-Brügge U. 2007; Characterisation and management of healthcare onset Clostridium difficile associated diarrhoea in a hyperendemic region in Germany. In Abstracts of the 17th European Congress of Clinical Microbiology and Infectious Diseases Munich: 31 March–4 April 2007 Abstract 1733_1419 http://www.blackwellpublishing.com/eccmid17/abstract.asp?id=57718
    [Google Scholar]
  34. Zafar A. B., Gaydos L. A., Furlong W. B., Nguyen M. H., Mennonna P. A. 1998; Effectiveness of infection control program in controlling nosocomial Clostridium difficile . Am J Infect Control 26:588–593 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.47711-0
Loading
/content/journal/jmm/10.1099/jmm.0.47711-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error